Approval · Notice of Compliance 33626 · 2024
RIXIMYO: Notice of Compliance 33626
Issued July 11, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33626
- Date
- July 11, 2024
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
- Canadian reference product
- RITUXAN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIXIMYO | Not yet assigned | — |
Medicinal ingredients
- RITUXIMAB 10 MG per ML